Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(17%)
Results Posted
67%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
1
17%
Ph phase_4
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

active_not_recruiting117%
completed350%
terminated233%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruiting

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

NCT07757568
terminatedphase_2

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

NCT02975349
completedphase_4

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

NCT02739542
completedphase_1

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

NCT04022473
completed

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

NCT02823951
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07757568

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

Active Not Recruiting
NCT02975349Phase 2

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Terminated
NCT02739542Phase 4

Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

Completed
NCT04022473Phase 1

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

Completed
NCT02823951

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Completed
NCT02218879

Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6